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Abstract
Introduction and Objectives: To estimate the cost-effectiveness and cost-utility of ticagrelor
in the treatment of patients with acute coronary syndromes (unstable angina or myocardial
infarction with or without ST-segment elevation), including patients treated medically and those
undergoing percutaneous coronary intervention or coronary artery bypass grafting.
Methods: A short-term decision tree and a long-term Markov model were used to simulate the
evolution of patients’ life-cycles. Clinical effectiveness data were collected from the PLATO
trial and resource use data were obtained from the Hospital de Santa Marta database, diagnosis-
related group legislation and the literature.
Results: Ticagrelor provides increases of 0.1276 life years and 0.1106 quality-adjusted life years
(QALYs) per patient. From a societal perspective these clinical gains entail an increase in expen-
diture of D 610. Thus the incremental cost per life year saved is D 4780 and the incremental
cost per QALY is D 5517.
Conclusions: The simulation results show that ticagrelor reduces events compared to clopido-
grel. The costs of ticagrelor are partially offset by lower costs arising from events prevented.
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The use of ticagrelor in clinical practice is therefore cost-effective compared to generic clo-
pidogrel.
© 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights
reserved.
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Avaliac¸ão económica de ticagrelor em prevenc¸ão secundária pós Síndroma Coronário
Agudo
Resumo
Introduc¸ão e objetivos: Estimar os rácios custo-efetividade e custo-utilidade da utilizac¸ão de
ticagrelor versus clopidogrel no tratamento de doentes com síndromas coronárias agudas
(angina instável, enfarte do miocárdio sem elevac¸ão ST [NSTEMI] ou enfarte do miocárdio com
elevac¸ão ST [STEMI]); incluindo doentes sujeitos a tratamento médico e aqueles geridos com
intervenc¸ão coronária percutânea (ICP) ou bypass aortocoronário com enxerto (CABG).
Metodologia: Foi utilizada uma árvore de decisão de curto prazo e um modelo de Markov de
longo prazo para simular a progressão dos doentes no decurso da sua vida. Os dados de eﬁcácia
clínica foram recolhidos a partir do ensaio clínico PLATO e os dados de consumo de recursos
foram obtidos na Contabilidade Analítica do Hospital de Santa Marta, legislac¸ão dos GDH e
consulta de bibliograﬁa disponível.
Resultados: Ticagrelor proporciona, a cada doente, um incremento de 0,1276 anos de vida e
0,1106 QALY. Na perspectiva da sociedade, estes ganhos implicam um aumento da despesa em
610D . Obtêm-se, assim, um custo incremental por ano de vida salvo de 4780D e um custo
incremental por QALY de 5517D .
Conclusões: Os resultados obtidos mostram que o ticagrelor diminui a quantidade de eventos,
quando comparado com clopidogrel. Os custos com ticagrelor são parcialmente compensados
por uma diminuic¸ão dos custos decorrentes dos eventos evitados. Assim, a utilizac¸ão de tica-
grelor na prática clínica portuguesa é custo-efetiva quando comparado com a abordagem com
clopidogrel.
© 2014 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os
direitos reservados.
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ACS acute coronary syndromes
ADP adenosine diphosphate
CABG coronary artery bypass grafting
DRG diagnosis-related group
ICER incremental cost-effectiveness ratio
ICUR incremental cost-utility ratio
MI myocardial infarction
NSTEMI non-ST-segment myocardial infarction
PCI percutaneous coronary intervention
ProACS Portuguese Registry on Acute Coronary Syn-
dromes
QALY quality-adjusted life year
STEMI ST-segment elevation myocardial infarction
UA unstable angina
VAT value-added tax
ntroduction
ardiovascular disease is the leading cause of death in
ortugal, accounting for 32.3% of all deaths in 2007 accord-
ng to a 2008 report from the Portuguese National Institute
f Statistics. According to the Portuguese High Commissar-
at for Health in 2007, of cardiovascular deaths, 44.9% were
p
r
aue to cerebrovascular disease and 23.1% to ischemic heart
isease, particularly acute coronary syndromes (ACS).
ACS represent a life-threatening manifestation of
therosclerosis usually precipitated by acute thrombosis,
nduced by a ruptured or eroded atherosclerotic plaque,
ith or without concomitant vasoconstriction, causing a sud-
en and critical reduction in blood ﬂow. This triggers a
ascade of reactions resulting in the formation of a coronary
hrombus that completely or partially obstructs the arterial
umen.1,2
ACS are a group of clinical conditions, all of which share
common pathophysiological substrate, that of unstable
therothrombotic coronary disease: ST-segment elevation
yocardial infarction (MI) (STEMI), non-ST-segment MI
NSTEMI), and unstable angina (UA).1,2
The Portuguese Registry on Acute Coronary Syndromes
ProACS), the main source of information on ACS in Portu-
al, was established in 2002 with the purpose of analyzing
he clinical characteristics, treatment and outcomes of
CS patients, monitoring changes over time, and assessing
ompliance with the guidelines on ACS. A total of 22 482
atients were included between 2002 and 2009, with a
ean age of 66±13 years, 70% male, of whom 45.4% were
iagnosed with STEMI, 41.4% with NSTEMI and 13.1% with
A.3
Platelet activation plays an important part in the patho-
hysiology of ACS, not only in cases of acute plaque
upture, but also as a contributing factor for subsequent
therothrombotic events in the systemic circulation of
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Table 1 Characteristics of the base-case population.
Ticagrelor group (n=9333) Clopidogrel group (n=9291)
Median age, years 62 62
Age ≥75 years, n (%) 1396 (15.0) 1482 (16.0)
Female, n (%) 2655 (28.4) 2633 (28.3)
Median BMI, kg/m2 (range) 27 (13--68) 27 (13--70)
BMI: body mass index.
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are three main types of antiplatelet drug: cyclooxygenase
inhibitors (most commonly aspirin); adenosine diphosphate
(ADP) receptor inhibitors (the thienopyridines ticlopi-
dine, clopidogrel, and prasugrel); and glycoprotein IIb/IIIa
inhibitors, including tiroﬁban, eptiﬁbatide, and abciximab.4
Ticagrelor (trade name Brilique® in Europe) is a non-
heparin antiplatelet drug that is the ﬁrst orally active
reversible P2Y12 receptor antagonist of a new chemi-
cal class, the cyclopentyl-triazolo-pyrimidines.5 Like the
thienopyridines, ticagrelor blocks P2Y12, an ADP receptor,
and thereby inhibits ADP-mediated platelet activation and
aggregation. However, unlike thienopyridines, which are
irreversible, ticagrelor binds directly and reversibly to P2Y12
and non-competitively inhibits signal transduction.
Methods
The present study estimates the cost-effectiveness and
cost-utility of ticagrelor (loading dose, 90 mg twice daily
thereafter) vs. clopidogrel (loading dose, 75 mg daily there-
after) in the treatment of patients with ACS.
The effects were measured in life years saved and
quality-adjusted life years (QALYs). Clinical effectiveness
data were collected from the PLATO trial. The main
endpoints were death from any cause, MI and non-fatal
stroke.
The main characteristics of the population used in
the model, based on the PLATO trial, are shown in
Table 1.
The time horizon was set at a patient’s lifetime in order to
assess the long-term impact of therapy on health outcomes
and associated costs.
The analysis was conducted from a societal perspective in
accordance with the Portuguese Ministry of Health’s guide-
lines for economic evaluation studies of drugs,6 in which
the costs and effects for all parties involved are taken into
account, including indirect costs.
Clinical effectiveness
PLATO7 was a multicenter, double-blind, randomized trial
comparing ticagrelor (180-mg loading dose, 90 mg twice
daily thereafter) and clopidogrel (300--600-mg loading dose,
75 mg daily thereafter) for the prevention of cardiovascu-
lar events in 18 624 patients hospitalized with ACS with or
without ST-segment elevation.
r
a
e
tThe primary endpoint was a composite of death from
ascular causes, MI, or stroke, measured as the number of
vents. At 12 months, the primary endpoint had occurred in
.8% of patients receiving ticagrelor compared with 11.7%
f those receiving clopidogrel (hazard ratio [HR], 0.84; 95%
onﬁdence interval, 0.77--0.92; p<0.001).
odel
he model used to evaluate ticagrelor was adapted for
he Portuguese situation from a European model (Nikolic
t al.8). This model, which has been the subject of several
ublications, consists of two parts: a short-term decision
ree for the ﬁrst year based on data from the PLATO trial,
nd a Markov model for long-term extrapolation, in order
o cover all the major events associated with resource
se and clinical outcomes during a patient’s lifetime. The
odel is similar to other decision analysis models on
CS.9--11
Figure 1 illustrates the model structure.
In the ﬁrst year, patients are allocated to nodes in the
ecision tree according to the estimated probability of suf-
ering each event, which differs between the two treatment
trategies according to the treatment effect observed in the
LATO trial. Each node is assigned estimates of health care
se and QALYs.
After the ﬁrst year, it is assumed that patients are no
onger on treatment with ticagrelor or clopidogrel, without
irect repercussions (treatment effects or post-treatment
elapse) for the cycles of the Markov model.
The Markov cycles have a duration of one year. Each
ealth state is associated with an estimate of health-related
uality of life expressed in QALYs and of health resource use.
he patient cohort progresses through the Markov model
ccording to the estimated probability of transition based
n the PLATO data.
In each year patients without events have a risk of suffer-
ng non-fatal MI or non-fatal stroke (transitions 1 and 2); in
he case of a non-fatal event, patients progress to the ‘‘Non-
atal MI’’ or ‘‘Non-fatal stroke’’ state. Patients at the ‘‘No
vent’’ state are also at risk of death (transition 3) every
ear, and if this occurs, they progress to the ‘‘Death’’ state,
n absorbing state following which no further transitions are
ossible.
The states ‘‘Non-fatal MI’’ and ‘‘Non-fatal stroke’’ rep-
esent the ﬁrst-year outcome in terms of survival, costs
nd quality of life of patients who suffered a non-fatal
vent, but who are still at risk of dying and thus moving
o the ‘‘Dead post event’’ state (transitions 4 and 5); the
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ACS patients
(trial entry)
No further event
Non-fatal MI
Non-fatal stroke
Death
Dead
Dead3
1 2
4
6 7
Post stroke
Non-fatal
MI
Non-fatal
stroke
Dead post
event
5Post stroke
Post MI
No event
Start state in
long-term
Markov model
One-year decision tree based
on PLATO data
Long-term Markov extrapolation model
Post MI
No event
Figure 1 Model structure (adapted from Nicolic et al.8). ACS: acute coronary syndrome; MI: myocardial infarction.
Table 2 Estimated transition probabilities for the short-
term decision tree.
All ACS Clopidogrel Ticagrelor
Death from any cause 0.0586 0.0462
Non-fatal MI 0.0575 0.0497
Non-fatal stroke 0.0088 0.0096
No further event 0.8751 0.8945
ACS: acute coronary syndromes; MI: myocardial infarction.
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tates, meaning that patients can only remain in them for
ne cycle. Patients who are still alive after a year pass to
he ‘‘Post MI’’ or ‘‘Post stroke’’ states, which like the ‘‘Non-
atal MI’’ and ‘‘Non-fatal stroke’’ states represent patients’
utcomes in terms of survival, costs and quality of life in
he second and subsequent years after a non-fatal event
ollowing entry to the PLATO trial.
The ‘‘Post MI’’ and ‘‘Post stroke’’ states are associated
ith risk of death (transitions 6 and 7) as well as with costs
nd QALYs.
hort-term calibration of the modelor short-term calibration of the model, the probabilities
ere based on data from the PLATO trial (Table 2). Four
a
w
lransition probabilities were obtained to calibrate the
ecision tree nodes:
. The probability of non-fatal MI;
. The probability of non-fatal stroke;
. The probability of death from any cause;
. The probability of having no further event, deﬁned as the
difference between 1 and the sum of the probabilities of
the other three events.
ong-term extrapolation model
t the end of the ﬁrst year, there are differences between
atients treated with ticagrelor and clopidogrel, reﬂected in
he distribution between the different health states. In the
ong-term model no patients are receiving either medication
nd so the transition probabilities are the same for both
rms. Even so, the long-term treatment effects differ as a
unction of the different starting points.
The annual mortality risks in the ‘‘No event’’ state (tran-
ition 3) are estimated using age-speciﬁc mortality rates
aken from Portuguese life tables.12 It should be borne in
ind that patients in this state have been event-free for
t least a year since the initial ACS, and the evidence sug-
ests that ACS patients are at greater risk of suffering a
atal event in the following 12 months, the risk decreasingge and gender to incorporate the increased risk associated
ith ACS. A standard deviation of 0.10 was assumed for the
ogarithm of the HR for the probabilistic sensitivity analysis
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Table 3 Transition parameters of the Markov model.
Mean value Distributionb
Annual risk of MI in the ‘‘No event’’ state 0.019 Based on the same regression of values used in
the decision tree
Annual risk of stroke in the ‘‘No event’’ state 0.003 Based on the same regression of values used in
the decision tree
Risk of death in the ‘‘No event’’ statea 2.000 0.69 (0.10)
Risk of death in the ‘‘Non-fatal MI’’ statea 6.000 1.79 (0.30)
Risk of death in the ‘‘Post MI’’ statea 3.000 1.10 (0.15)
Risk of death in the ‘‘Non-fatal stroke’’ statea 7.430 2.01 (0.35)
Risk of death in the ‘‘Post stroke’’ statea 2.070 0.73 (0.10)
a Hazard ratio in relation to standardized mortality.
b Normal on the logarithmic scale with mean (standard deviation).
The transition parameters of the Markov model in the
base case are summarized in Table 3.
Utility in the short-term model
The estimates of utility used in each node of the decision
tree were based on EQ-5D questionnaire data11 collected
within the PLATO study.
The mean QALYs for each node were estimated using
ordinary least squares regression with the nodes and treat-
ment groups introduced as dummy variables. The equations
include age and gender as explanatory variables to allow
estimates of QALYs for different ages and for men and
women separately.
The mean estimated QALYs for each node and for each
treatment group are presented in Table 4.
Utility in the long-term model
For the ‘‘No event’’ state the estimate of QALYs for event-
free patients in the PLATO trial was used. The mean estimate
of ticagrelor- and clopidogrel-treated patients (0.875) was
applied for patients aged <70 years. When men and women
were analyzed separately, the estimated QALYs for menwere
0.05 higher for men than for women; the estimate also
varies with age at trial entry, and as patients grow older
in the model, a proportional decrement due to age was
applied.
The QALY estimates for the Markovmodel are summarized
in Table 5.
Table 4 Estimated QALYs for each node of the decision
tree.
Clopidogrel Ticagrelor
Death from any cause 0.2503 0.2473
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on the logarithmic scale.
For the ‘‘Non-fatal MI’’ state (transition 4), the mortality
risk observed in the PLATO trial was compared to the risk
in the life tables and an HR of 6 was applied. A standard
deviation of 0.3 was assumed for the logarithm of the HR
for the probabilistic sensitivity analysis and this ratio was
assumed to follow a normal distribution on the logarithmic
scale.
For the ‘‘Non-fatal stroke’’ state (transition 5), the rela-
tive mortality risk in the ﬁrst year after ACS compared with
age- and gender-matched individuals in the general popu-
lation was based on the results of three studies.15--17 The
study by Dennis et al.,15 with a risk of 7.43, was consid-
ered the most robust since it had the longest follow-up and
the largest number of patients. As there were more cases
of ACS in the ticagrelor group, it was decided to use 7.43
as a conservative ﬁgure in the analysis of this treatment.
A standard deviation of 0.35 on the logarithmic scale was
assumed.
For the transition from ‘‘Post MI’’ to ‘‘Dead’’ (transition
6), it was assumed that patients in the ‘‘Post MI’’ state, hav-
ing suffered reinfarction, are at higher risk than patients
in the ‘‘No event’’ state. Patients in the ‘‘Post MI’’ state
have survived a year after the recurrent event and have
a lower mortality risk than those in the ‘‘Non-fatal MI’’
state. It is therefore likely that the risk of patients in the
‘‘Post MI’’ state is between that of the ‘‘No event’’ and
‘‘Non-fatal MI’’ states. An HR of 3 was accordingly applied
to maintain the logical consistency of the values in the
model’s parameters. A standard deviation of 0.15 on the log-
arithmic scale was assumed for the probabilistic sensitivity
analysis.
For the ‘‘Post stroke’’ state (transition 7), the studies
used are highly consistent in their attribution of mortal-
ity risk in the second and subsequent years after the initial
stroke.18 The ﬁgure of 2.07, from Dennis et al.,15 was taken
as the relative mortality risk in the ﬁrst year, while for the
second and subsequent years it was taken as the mean of
the other years of follow-up, which was consistent from the
second year onwards. A standard deviation of 0.10 on the
logarithmic scale was assumed for the probabilistic sensitiv-
ity analysis.
Non-fatal MI 0.8136 0.8106
Non-fatal stroke 0.7379 0.7349
No further event 0.8763 0.8732
MI: myocardial infarction.
22
Table 5 QALY estimates for the Markov model.
Mean value
QALY weight in the ‘‘No
event’’ state, age <70 years
0.8748
QALY weight in the ‘‘No event’’
state, age 70--79 years
0.8400
QALY weight in the ‘‘No
event’’ state, age >79 years
0.7814
Annual QALY decrement in the
‘‘Non-fatal MI’’ state
0.0627
Annual QALY decrement in the
‘‘Post MI’’ state
0.0627
Annual QALY decrement in the
‘‘Non-fatal stroke’’ state
0.1384
Annual QALY decrement in the
‘‘Post stroke’’ state
0.1384
MI: myocardial infarction.
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ndirect costs
he model design only allows indirect costs to be added
o events in the ﬁrst year, which means the effects of
orbidity on the population’s productivity are underesti-
ated, since some events will not occur until after the ﬁrst
ear.
The estimated mean annual productivity in 2010 for those
ged >60 was D 15 743 for men and D 10 839 for women,
orresponding to mean daily productivity of D 68.50 and
47.12, respectively. These ﬁgures were not updated for
012, which is reasonable given the state of the labor market
nd salaries in Portugal in recent years.
The absenteeism associated with an event is taken to
e the number of working days equal to the mean hos-
ital stay plus twice this number for convalescence. On
he basis of the diagnosis-related groups (DRGs) in force
n 2009, the mean hospital stay for stroke survivors was
alculated as 10.3 days and for MI survivors as 7.9 days.
bsenteeism is thus 30.9 days for stroke and 23.7 days for
I, the corresponding costs being calculated as the prod-
ct of days lost, daily cost, and post-event employment
ates.The employment rates used in the calculations are shown
n Table 6.
The cost of lost employment due to early retirement
as based on the assumption that leaving the labor market
T
a
d
i
Table 6 Employment rates in individuals aged 60 and over.
Men
General population 22.5%
Population with one event 19.3%
Population with two events 15.2%
Source: Portuguese National Health Survey 2005/2006 and authors’ anaM. Gouveia et al.
educes productivity by at least 2.5 years on average,
orresponding to an example in which the mean age for the
nalysis is taken to be 62.5 years and normal retirement is
t age 65.
osts of ticagrelor and the comparator clopidogrel
reatment with ticagrelor should begin with a single loading
ose of 180 mg (two 90-mg tablets) followed by 90 mg twice
aily. The daily cost of ticagrelor is thus D 2.67 (retail price
ithout value added tax [VAT]).
The daily cost of clopidogrel, which at the time of the
nalysis was D 0.32, was estimated on the basis of 75 mg
aily at the reference price of the corresponding ‘homoge-
eous group’ of medications (GH0736), without VAT.
ther direct costs
ther direct costs, including those related to the use of
ealth care services (hospitalization, consultations, other
edications, diagnostic exams, other treatments, etc.),
ere estimated separately for each node of the deci-
ion tree (ﬁrst year) and subsequent cycles of the Markov
odel.
For the ﬁrst year, Portuguese unit costs and the resource
se data from the PLATO study were used, while updated
stimates of the direct costs generated in the ﬁrst year were
sed for subsequent cycles.
In the event of differences between the estimates based
n PLATO data and more precise estimates based on typi-
al resource use patterns in the Portuguese health system,
sensitivity analysis was performed for the parameters in
uestion.
Estimates of unit costs are generally based on the DRGs
n force and audit information from the cardiology and
ardiothoracic surgery departments of Hospital de Santa
arta.
The results are shown in Table 7.
For subsequent cycles, updated estimates of the direct
osts generated in the ﬁrst year and for following years were
sed for MI and stroke (Table 8).
esults
ase casehe model’s time horizon was set at a patient’s lifetime
nd an annual discount rate of 5% was applied, in accor-
ance with the guidelines for economic evaluation studies
n Portugal.6
Women Total
12.8% 17.0%
4.5% 13.1%
0% 12.6%
lysis.
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Table 7 Costs in the ﬁrst year in the base case.
Events in the ﬁrst year Costs (D )
Clopidogrel group, no event 7656
Ticagrelor group, no event 7456
Clopidogrel group, MI 15 258
Ticagrelor group, MI 15 058
Clopidogrel group, stroke 14 943
Ticagrelor group, stroke 14 742
Clopidogrel group, death 12 291
Ticagrelor group, death 12 091
MI: myocardial infarction.
Table 8 Direct costs after the ﬁrst year in the base case.
Direct costs of the model
cycles and medications
Costs (D )
Cost of ‘‘MI’’ in the ﬁrst year 7834.74
Cost of ‘‘MI’’ in the 2nd and
subsequent years (Markov
model)
772.36
Cost of ‘‘Stroke’’ in the ﬁrst
year
7220.99
Cost of ‘‘Stroke’’ in the 2nd
and subsequent years
(Markov model)
531.37
Cost of ‘‘No event’’ (Markov
model)
651.87
MI: myocardial infarction.
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Figure 2 Distribution of incremental costs and QALYs. QALY:
quality-adjusted life year.
0.0
0.1
 0.2
 0.3
0.4
0.5
0.6
0.7
0.8
 0.9
 1.0
30 00025 00020 00015 00010 00050000
Pr
ob
ab
ilit
y 
tic
ag
re
lo
r i
s 
co
st
-e
ffe
ct
ive
 
Willingness to pay per QALY
Figure 3 Cost-effectiveness acceptability curve for tica-
g
U
A
n
i
t
t
c
s
w
e
(
P
A
f
t
r
g
i
i
1
d
a
a
a
D
p
D
Table 9 Results of cost-effectiveness and cost-utility analysis.
Ticagrelor Clopidogr
Costs (D ) 16 226 15 616
Life years 9.8051 9.6775
QALYs 8.2942 8.1836
ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-util
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nivariate sensitivity analysis
sensitivity analysis is designed to determine the robust-
ess of the results in relation to the assumptions made
n the analysis when the available information is uncer-
ain. A univariate sensitivity analysis was performed for the
ime horizon, exclusion of indirect costs, alternative dis-
ount rates and alternative costings for events. This analysis
howed that the cost-effectiveness and cost-utility values
ere robust, since in all scenarios the incremental cost-
ffectiveness ratio (ICER) and incremental cost-utility ratio
ICUR) were acceptable (less than D 20 000/QALY).
robabilistic sensitivity analysis
second-order Monte Carlo simulation was used to account
or the uncertainty arising from single model inputs, so
hat the uncertainty of the cost-effectiveness analysis
eﬂects the uncertainty in the decision to implement a
iven treatment rather than the uncertainty of the model
nputs.19,20 The distribution of incremental costs and QALYs
s represented graphically in Figure 2, which is based on
0 000 simulations of the model.
The probabilities of ticagrelor being cost-effective at
ifferent levels of willingness to pay for one QALY (accept-
bility curve) were also estimated (Figure 3).
The mean ICUR in the simulation was D 5517/QALY; for
willingness to pay of D 5541/QALY there is a 50% prob-
bility of acceptance. The 95% conﬁdence intervals are
2314/QALY for 2.5 percentile and D 11 790/QALY for 97.5
ercentile, well below the usual acceptability threshold of
20 000/QALY.
el Difference ICER/ICUR
610
0.1276 4.780
0.1106 5.517
ity ratio; QALY: quality-adjusted life year.
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iscussion
he results were robust in a variety of univariate anal-
ses and alternative scenarios. In some cases, when the
ources of cost estimates of events were changed, such as
xcluding indirect costs, the incremental ratios are higher,
ut only slightly (2.4%). When the time horizon is reduced
he incremental ratios are up to twice as high as the base
ase. In these cases the ICERs and ICURs change signiﬁ-
antly, but even in the worst scenarios they remain less than
20 000/QALY (Table 9).
onclusions
ll the results of this economic evaluation comparing tica-
relor and clopidogrel for secondary prevention following
CS show that ticagrelor has excellent levels of cost-
ffectiveness, producing health gains at costs well below
he acceptable thresholds for willingness to pay on the part
f the Portuguese National Health Service.
The results were robust in a variety of univariate analyses
nd alternative scenarios.
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